TransCode Therapeutics Quote - RNAZ

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.5918

Bid

0.5861

Ask

0.6095

Volume

3,777,949

0.478 Day's Range 0.6782

0.216 52 Week Range 21.20

Market Cap

10.218M

Previous Close

0.4965

Open

0.4995

Last Trade

4800

0.5918

(formt)

Last Trade Time

Financial Volume

US$ 2,263,684

VWAP

0.599183

Average Volume (3m)

1,940,287

Shares Outstanding

17,265,658

Dividend Yield

PE Ratio

-0.58

Earnings Per Share (EPS)

-1.07

Revenue

Net Profit

-18.55M

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regre... TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.transcodetherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

TransCode Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAZ. The last closing price for TransCode Therapeutics was US$0.50. Over the last year, TransCode Therapeutics shares have traded in a share price range of US$ 0.216 to US$ 21.20.

TransCode Therapeutics currently has 17,265,658 shares outstanding. The market capitalization of TransCode Therapeutics is US$8.57 million. TransCode Therapeutics has a price to earnings ratio (PE ratio) of -0.58.

Form 8-K - Current report

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancerTTX-MC138 is an antisense...

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0682	-10.3333333333	0.66	0.73	0.41	2105022	0.58954869	CS
4	0.3467	141.45246838	0.2451	0.73	0.2226	3226824	0.4284279	CS
12	-0.3082	-34.2444444444	0.9	0.98	0.216	1940287	0.37334589	CS
26	-0.0832	-12.3259259259	0.675	2.01	0.216	1540155	0.65325914	CS
52	-19.4082	-97.041	20	21.2	0.216	2260520	8.31439081	CS
156	-2295.4082	-99.9742247387	2296	2768	0.216	1454505	232.16432447	CS
260	-4799.4082	-99.9876708333	4800	5600	0.216	1707185	874.79989352	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
EVGOEVgo Inc	US$ 6.33 (61.07%)	115.63M
ELABElevai Labs Inc	US$ 0.1307 (53.40%)	470.14M
IPDNProfessional Diversity Network Inc	US$ 0.983 (34.66%)	1.53M
VRCAVerrica Parmaceuticals Inc	US$ 1.4411 (29.83%)	10.97M
WHLRWheeler Real Estate Investment Trust Inc	US$ 16.91 (26.29%)	6.24M
ADDColor Star Technology Company Ltd	US$ 0.45 (-57.14%)	10.84M
CETXCemtrex Inc	US$ 2.56 (-51.07%)	4.02M
SOBRSOBR Safe Inc	US$ 4.3749 (-31.64%)	150.3k
PWMPrestige Wealth Inc	US$ 0.9101 (-30.30%)	387.61k
AREBAmerican Rebel Holdings Inc	US$ 2.78 (-29.26%)	861.31k
ELABElevai Labs Inc	US$ 0.1307 (53.40%)	514.81M
NVDANVIDIA Corporation	US$ 122.85 (3.37%)	277.58M
KXINKaixin Holdings	US$ 0.4311 (26.02%)	175.03M
PEGYPineapple Energy Inc	US$ 0.1374 (19.58%)	174.67M
MLGOMicroAlgo Inc	US$ 0.3492 (12.65%)	163.83M